Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: E_K_S who wrote (46374)	1/31/2012 3:32:40 PM
From: Paul Senior	Respond to of 78783

Big pharma: Thanks for the update. I'm suspicious of the effect of upcoming patent expirations on these stocks. I've not followed MRK or PFE closely --- sorry I missed the lows at last year's sell-off. I have NVS on my watch list, and have waffled on whether I want to buy or not. It's selling nearer 12-mo lows than highs. Unlike PFE&MRK. The forward p/e is 9+, so I assume analysts have baked expirations into that number. PFE forward p/e is 9+ also, and that company is to have a very big expiration this year I believe, so I wonder about relying on forward p/e estimates here. Maybe SNY, also forward p/e 9, a Buffett pick, might be considered. Meanwhile in pharma, I hold shares of these: finance.yahoo.com Only stock I like here currently is NVO, which imo is not a value stock. I'm betting on the growth in obesity, the associated increase in diabetes, and NVO's ability to treat that disease. If I didn't already own shares, I'd consider it for as a buy for a growth-stock pick.